demonstrated a larger prototype<\/a> (24 by 8 by 8 feet) for the continuous integrated manufacturing of drugs from chemical synthesis to tablets. That project has ended, but the continuous manufacturing initiative, funded by Novartis, is still underway as the researchers develop new methods for synthesis, purification, and formulation.<\/p>\nIn the new endeavor, funded by the Defense Advanced Research Projects Agency (DARPA), the MIT researchers built on what they learned from the Novartis-funded project to create a much smaller, transportable device. Their new system can produce four drugs formulated as solutions or suspensions \u2014 Benadryl, lidocaine, Valium, and Prozac. Using this apparatus, the researchers can manufacture about 1,000 doses of a given drug in 24 hours.<\/p>\n
Key to the continuous system is the development of chemical reactions that can take place as the reactants flow through relatively small tubes as opposed to the huge vats in which most pharmaceutical reactions now take place. Traditional batch processing is limited by the difficulty of cooling these vats, but the flow system allows reactions that produce a great deal of heat to be run safely.<\/p>\n
\u201cIn many cases we were developing syntheses of targets that had never been done in a continuous flow platform,\u201d Jamison says. \u201cThat presents a lot of challenges even if there is a good precedent from the batch perspective. We also recognized it as an opportunity where, because of some of the phenomena that one can leverage in [a flow-based system], you can make molecules differently.\u201d<\/p>\n
The chemical reactions required to synthesize each drug take place in the first of two modules. The reactions were designed so that they can take place at temperatures up to 250 degrees Celsius and pressures up to 17 atmospheres.<\/p>\n
By swapping in different module components, the researchers can easily reconfigure the system to produce different drugs. \u201cWithin a few hours we could change from one compound to the other,\u201d Jensen says.<\/p>\n
In the second module, the crude drug solution is purified by crystallization, filtered, and dried to remove solvent, then dissolved or suspended in water as the final dosage form. The researchers also incorporated an ultrasound monitoring system that ensures the formulated drug solution is at the correct concentration.<\/p>\n
Small-scale manufacturing<\/strong><\/p>\nJohn Lewin, the division director of critical care and surgery pharmacy at Johns Hopkins Hospital, says this type of manufacturing could bring down production costs and help patients get better access to the drugs they need.<\/p>\n
\u201cThis sets the foundation for a new paradigm in terms of the way we manufacture pharmaceuticals and distribute them to patients,\u201d says Lewin, who was not involved in the study. \u201cSuch a device could really meet a lot of the supply chain challenges here in the U.S. and around the world.\u201d<\/p>\n
One of the advantages of this small-scale system is that it could be used to make small amounts of drugs that would be prohibitively expensive to make in a large-scale plant. This would be useful for so-called \u201corphan drugs\u201d \u2014 drugs needed by a small number of patients. \u201cSometimes it\u2019s very difficult to get those drugs, because economically it makes no sense to have a huge production operation for those,\u201d Jensen says.<\/p>\n
It could also be useful in regions with few pharmaceutical storage facilities, because drugs can be produced on demand, eliminating the need for long-term storage.<\/p>\n
\u201cThe idea here is you make what you need, and you make a simple dosage form, because they\u2019re going to be taken on demand. The dosages don\u2019t have to have long-term stability,\u201d Myerson says. \u201cPeople line up, you make it, and they take it.\u201d<\/p>\n
The researchers are now working on the second phase of the project, which includes making the system about 40 percent smaller and producing drugs whose chemical syntheses are more complex. They are also working on producing tablets, which are more complicated to manufacture than liquid drugs.<\/p>\n<\/div>\n<\/div>\n<\/div>\n
Fuente:<\/strong> http:\/\/news.mit.edu<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Investigadores del MIT han desarrollado un sistema compacto y port\u00e1til de fabricaci\u00f3n de productos farmac\u00e9uticos que puede configurarse para producir una variedad de f\u00e1rmacos a… <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[29,24],"tags":[],"_links":{"self":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts\/943"}],"collection":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=943"}],"version-history":[{"count":0,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts\/943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"This](\"http:\/\/news.mit.edu\/sites\/mit.edu.newsoffice\/files\/styles\/news_article_image_top_slideshow\/public\/images\/2016\/MIT-Pharma-continue-edit-2_0.jpg?itok=NM_ZFvqe\" "\\"\\"")
MIT researchers have developed a compact, portable pharmaceutical manufacturing system that can be reconfigured to produce a variety of drugs on demand.<\/p>\n